Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.